Yves Benhamou

Summary

Country: France

Publications

  1. ncbi request reprint In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir
    Olivier Lada
    Virology, AP HP Pitié Salpêtrière Hospital, Paris, France
    Antivir Ther 9:353-63. 2004
  2. ncbi request reprint A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS, Paris, France
    Clin Chem 52:1887-96. 2006
  3. doi request reprint Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial
    Yves Benhamou
    Service d Hépato Gasteroentérologie, Hopital Pitie Salpetriere, Paris, France
    J Infect Dis 208:1000-7. 2013
  4. pmc The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010
    Marc Arthur Loko
    INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
    BMC Infect Dis 10:303. 2010
  5. pmc Hepatic profile analyses of tipranavir in Phase II and III clinical trials
    Jaromir Mikl
    SUNY at Albany, School of Public Health, Rensselaer NY, USA
    BMC Infect Dis 9:203. 2009
  6. ncbi request reprint Treatment algorithm for chronic hepatitis B in HIV-infected patients
    Yves Benhamou
    Hopital Pitie Salpetriere, Service d Hepato Gastroenterologie, 27 boulevard de l Hopital, 75013 Paris, France
    J Hepatol 44:S90-4. 2006
  7. ncbi request reprint Hepatitis B in the HIV-coinfected patient
    Yves Benhamou
    Service d Hepato gastro enterologie, Hospitalier Pitié Salpêtrière, Paris, France
    J Acquir Immune Defic Syndr 45:S57-65; discussion S66-7. 2007
  8. ncbi request reprint HIV-1/hepatitis B coinfection
    Yves Benhamou
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Expert Rev Anti Infect Ther 3:229-39. 2005
  9. ncbi request reprint [Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients]
    Yves Benhamou
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, 27 boulevard de l Hopital, 75013 Paris, France
    Gastroenterol Clin Biol 30:3S22-5. 2006
  10. ncbi request reprint Treatment of hepatitis B virus infection in patients coinfected with HIV
    Yves Benhamou
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, 27 boulevard de l Hopital, 75013 Paris, France
    Gastroenterol Clin North Am 33:617-27, x. 2004

Detail Information

Publications87

  1. ncbi request reprint In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir
    Olivier Lada
    Virology, AP HP Pitié Salpêtrière Hospital, Paris, France
    Antivir Ther 9:353-63. 2004
    ..The excellent activity of TDF on lamivudine-resistant virus independently of the resistance mutation profile offers an interesting treatment alternative to HIV-HBV coinfected patients...
  2. ncbi request reprint A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS, Paris, France
    Clin Chem 52:1887-96. 2006
    ..We compared the 5-year prognostic value of the FibroTest with biopsy staging for predicting cirrhosis decompensation and survival in patients with chronic HCV infection...
  3. doi request reprint Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial
    Yves Benhamou
    Service d Hépato Gasteroentérologie, Hopital Pitie Salpetriere, Paris, France
    J Infect Dis 208:1000-7. 2013
    ..This partially blinded, randomized, phase 2a C210 study evaluated the antiviral activity of telaprevir-based regimens in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 4 infection...
  4. pmc The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010
    Marc Arthur Loko
    INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
    BMC Infect Dis 10:303. 2010
    ..The ANRS CO 13 HEPAVIH cohort was set up to explore these critical questions.To describe the cohort aims and organization, monitoring and data collection procedures, baseline characteristics, as well as follow-up findings to date...
  5. pmc Hepatic profile analyses of tipranavir in Phase II and III clinical trials
    Jaromir Mikl
    SUNY at Albany, School of Public Health, Rensselaer NY, USA
    BMC Infect Dis 9:203. 2009
    ....
  6. ncbi request reprint Treatment algorithm for chronic hepatitis B in HIV-infected patients
    Yves Benhamou
    Hopital Pitie Salpetriere, Service d Hepato Gastroenterologie, 27 boulevard de l Hopital, 75013 Paris, France
    J Hepatol 44:S90-4. 2006
    ..Combination of TDF plus FTC or LAM should be proposed in patients with therapeutic indication for both viruses. TDF should be included in the anti-retroviral regiment of patients with HBV resistance to lamivudine...
  7. ncbi request reprint Hepatitis B in the HIV-coinfected patient
    Yves Benhamou
    Service d Hepato gastro enterologie, Hospitalier Pitié Salpêtrière, Paris, France
    J Acquir Immune Defic Syndr 45:S57-65; discussion S66-7. 2007
    ..Continuing drugs with anti-HBV activity is important, because stopping such therapy has been associated with HBV reactivation. Development of resistance is a risk with the long-term maintenance therapy required in most patients...
  8. ncbi request reprint HIV-1/hepatitis B coinfection
    Yves Benhamou
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Expert Rev Anti Infect Ther 3:229-39. 2005
    ..Reviews the epidemiology, natural history and the current status of treatment of HIV/hepatitis B coinfection...
  9. ncbi request reprint [Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients]
    Yves Benhamou
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, 27 boulevard de l Hopital, 75013 Paris, France
    Gastroenterol Clin Biol 30:3S22-5. 2006
  10. ncbi request reprint Treatment of hepatitis B virus infection in patients coinfected with HIV
    Yves Benhamou
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, 27 boulevard de l Hopital, 75013 Paris, France
    Gastroenterol Clin North Am 33:617-27, x. 2004
    ..This article highlights research into which treatments may be most effective for people with both hepatitis B virus infection and HIV. Studies from the era before highly active antiretroviral therapy and more recent studies are included...
  11. ncbi request reprint Antiretroviral therapy and HIV/hepatitis B virus coinfection
    Yves Benhamou
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, Paris, France
    Clin Infect Dis 38:S98-103. 2004
    ..However, further research is needed to determine the exact role of HBV and the mechanisms involved in antiretroviral-associated hepatotoxicity in HBV/HIV-coinfected patients...
  12. ncbi request reprint Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus
    Yves Benhamou
    Service d Héparo Gastroentérologie, Hopital Pitie Salpetriere, 27 boulevard de l Hopital, 75013 Paris, France
    J Hepatol 39:S194-9. 2003
  13. ncbi request reprint Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1
    Yves Benhamou
    Groupe Hospitalier Pitie Salpetriere, Service de d Hépato Gastroentérologie, Paris, France
    J Hepatol 44:62-7. 2006
    ..Adefovir dipivoxil (10 mg once-daily) was added to antiretroviral therapy including lamivudine in 35 HIV/HBV co-infected patients...
  14. ncbi request reprint Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients
    Yves Benhamou
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, Paris, France
    Hepatology 43:548-55. 2006
    ..In conclusion, this retrospective analysis demonstrates the efficacy of TDF against wild-type, presumed precore mutants and LAM-resistant HBV when used as a part of anti-retroviral therapy in HIV-coinfected patients...
  15. ncbi request reprint Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study
    Y Benhamou
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Lancet 358:718-23. 2001
    ..We assessed the safety and efficacy of a once daily dose of adefovir dipivoxil in an open-label trial for the treatment of lamivudine-resistant HBV infection in HIV-1-infected patients...
  16. ncbi request reprint [Non-viral liver infections in immunocompromised patients]
    Y Benhamou
    Service d Hepato gastro enterologie, groupe hospitalier La Pitié La Salpêtrière, 75651 Paris
    Rev Prat 51:2108-12. 2001
    ..Liver fungal infections have been reported in patients with T lymphocytes dysfunction, are mainly related to Candida species, but remain infrequent...
  17. ncbi request reprint Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy
    Y Benhamou
    Service d Hepato Gastroenterologie, Service de Pharmacie, Service de Virologie, Service de Maladies Infectieuses, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Hepatology 34:283-7. 2001
    ....
  18. ncbi request reprint Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
    Y Benhamou
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, Paris, France
    Hepatology 30:1302-6. 1999
    ..Lamivudine (300 mg/d) is effective for the inhibition of HBV replication in HIV-infected patients. However, emergence of lamivudine-resistant HBV may occur in 20% of patients per year...
  19. ncbi request reprint Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group
    Y Benhamou
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitié Salpêtrière and UPRES A 8067, Paris, France
    Hepatology 30:1054-8. 1999
    ..HIV seropositivity accelerates HCV-related liver fibrosis progression. In coinfected patients, a low CD4 count, alcohol consumption rate, and age at HCV infection are associated with a higher liver fibrosis progression rate...
  20. ncbi request reprint Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 13:895-900. 2008
    ..Adefovir dipivoxil (ADV) has shown its efficacy for treating 3TC-resistant (3TC-R) HBV in HIV-coinfected patients. ADV combined with pegylated interferon (PEG-IFN) has never been evaluated in this population...
  21. ncbi request reprint Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy
    Robert P Myers
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    AIDS 18:75-9. 2004
    ..Pegylated interferon alpha (PEG-IFN-alpha) and ribavirin is the most effective available treatment for chronic hepatitis C virus (HCV) infection. Its role in HIV/HCV-co-infected patients who have failed IFN-based therapy is unclear...
  22. doi request reprint Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies
    Thierry Poynard
    University Pierre and Marie Curie Liver Center, Paris, France
    Antivir Ther 15:617-31. 2010
    ..We aimed to review evidence-based published data of biomarkers that have been validated as non-invasive alternatives to biopsy as end points for HBV and HCV infection trials...
  23. pmc Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine
    Constance Delaugerre
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 46:1586-8. 2002
    ....
  24. ncbi request reprint Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B
    Dominique Thabut
    Hepato Gastroenterology Unit, Hopital Pitie Salpetriere, Paris, France
    Eur J Gastroenterol Hepatol 16:1367-73. 2004
    ..The clinical features, course and viral mutations associated with the emergence of viral resistance in this population have not been well studied...
  25. ncbi request reprint Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Clin Chem 50:1344-55. 2004
    ....
  26. ncbi request reprint Biomarkers of liver fibrosis
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    Adv Clin Chem 46:131-60. 2008
    ..Neither biomarkers nor biopsy are sufficient alone to take definitive decision in a given patient and all the clinical and biological data must be taken into account...
  27. ncbi request reprint Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B
    Robert P Myers
    Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Hepatol 39:222-30. 2003
    ..Liver biopsy is the gold standard for assessing hepatitis B virus (HBV)-related histology. The aim was to determine the diagnostic utility of noninvasive serum markers in patients with chronic hepatitis B...
  28. pmc Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers
    Thierry Poynard
    APHP Groupe Hospitalier Pitié Salpétrière, Universite Paris VI, CNRS UMR, Paris, France
    PLoS ONE 3:e3857. 2008
    ..The aim was to identify factors associated with LSM accuracy using FT as a non-invasive endpoint and vice versa...
  29. pmc An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS UMR 8149, Paris, France
    PLoS ONE 3:e2573. 2008
    ..We compared the 4-year prognostic value of combining FT-AT and viral load for a better definition of the inactive carrier status...
  30. doi request reprint Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    J Hepatol 56:49-54. 2012
    ..The course of the disease is determined by the rapidity of liver fibrosis progression (LFP). The influence of interferon on LFP in coinfected patients has yet not been evaluated by comparative liver biopsies...
  31. ncbi request reprint [What are the indications for treatment of acute hepatitis C?]
    Robert P Myers
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris
    Gastroenterol Clin Biol 26:B188-93. 2002
  32. doi request reprint Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
    Vlad Ratziu
    Hopital Pitie Salpetriere, Service d Hepatogastroenterologie, Universite Pierre et Marie Curie Paris VI, Assistance Publique Hopitaux de Paris, France
    Hepatology 51:445-53. 2010
    ..Likewise, there was no improvement in the NAS score, ballooning, intralobular inflammation, fibrosis stage, or area of fibrosis with 2 additional years of RSG in the RSG-RSG group...
  33. doi request reprint Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy
    Patrick Ingiliz
    Hepatology Department, AP HP, GH Pitié Salpétrière, Paris, France
    Hepatology 49:436-42. 2009
    ..Conclusions: HIV-infected patients on combined antiretroviral therapy with chronic transaminase elevation of unknown origin have a high rate of liver lesions, mostly consistent with NASH related to insulin resistance...
  34. ncbi request reprint Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection
    Nadia Alatrakchi
    Laboratoire d Immunologie Cellulaire et Tissulaire INSERM U543, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    AIDS 18:121-3. 2004
    ..This suggests that IFN+R therapy might compromise virus-specific immune defenses in immunosuppressed patients...
  35. ncbi request reprint Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    J Hepatol 48:35-42. 2008
    ..To analyze the barriers to HCV treatment in HIV-HCV co-infected patients and their evolution between 2004 and 2006...
  36. ncbi request reprint Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages
    Thierry Poynard
    Assistance Publique Hôpitaux de Paris Groupe Hospitalier Pitié Salpêtrière, Paris, France
    Clin Chem 53:1615-22. 2007
    ..The aim of this study was to assess the relationships between the AUC and the prevalence of each fibrosis stage and to elaborate simple methods of standardization...
  37. ncbi request reprint The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV
    Heidi Hannon
    Nephrology Department, Hôpital Pitié Salpétrière and CNRS UPRESA 8087, Paris, France
    Nephrol Dial Transplant 19:386-90. 2004
    ..Recently, lower doses of ADV were shown to be effective for the treatment of HIV-1 patients with chronic lamivudine (LAM)-resistant hepatitis B...
  38. doi request reprint The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption
    Francoise Imbert-Bismut
    Department of Biochemistry, APHP Groupe Hospitalier Pitié Salpétrière, Paris, France
    Eur J Gastroenterol Hepatol 21:18-27. 2009
    ..The aim was to improve the accuracy of the percentage of CDT by taking into account the presence of fibrosis and steatosis, estimated using biomarkers FibroTest and SteatoTest...
  39. ncbi request reprint Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients
    Robert P Myers
    Department of Hepatology and Gastroenterology, hôpital La Pitié Salpêtrière, Paris, France
    AIDS 17:721-5. 2003
    ..Our aim was to determine the operating characteristics of a non-invasive index of biochemical markers for the prediction of fibrosis in patients with HIV/HCV co-infection...
  40. ncbi request reprint Natural history and predictors of disease severity in chronic hepatitis C
    Julien Massard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Hepatol 44:S19-24. 2006
    ..The recent validation of non-invasive biomarkers should facilitate the study of fibrosis progression in large populations...
  41. doi request reprint Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study
    Stephanie Dominguez
    AP HP, Département de Maladies Infectieuses et Tropicales, INSERM U720, CHU Pitie Salpetriere, Paris, France
    J Antimicrob Chemother 65:2445-9. 2010
    ..To compare plasma antiretroviral concentrations in HIV-HCV co-infected and in matched HIV mono-infected patients...
  42. pmc Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants
    Olivier Lada
    Departments of Virology, Hepato Gastro Enterology, AP HP Pitié Salpêtrière Hospital, Paris, France
    J Virol 80:2968-75. 2006
    ..The consequences of this selection process with regard to vaccine efficacy, diagnosis, and clinical evolution remain partially unknown...
  43. doi request reprint Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial
    Vlad Ratziu
    Universite Pierre et Marie Curie Paris VI, Assistance Publique Hopitaux de Paris, Service d Hepatogastroenterologie, Paris, France
    Gastroenterology 135:100-10. 2008
    ..Nonalcoholic steatohepatitis (NASH) is a liver disease that complicates insulin-resistant states. This trial tested the efficacy and safety of rosiglitazone, an insulin-sensitizing agent, in patients with NASH...
  44. doi request reprint A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results
    Yves Benhamou
    Service d Hepato Gastroenterologie, hôpital La Pitié Salpêtrière, Paris, France
    Hepatology 50:717-26. 2009
    ..These results suggest fixed-dose VRD given 600 mg BID is insufficient to treat patients with chronic hepatitis C; a weight-based dosing trial of viramidine is currently under way...
  45. doi request reprint Ranking hepatologists: which Hirsch's h-index to prevent the "e-crise de foi-e"?
    Thierry Poynard
    UPMC, Service d Hepato Gastroenterologie, Paris Liver Center, Groupe Hospitalier Pitie Salpetriere, AP HP, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Clin Res Hepatol Gastroenterol 35:375-86. 2011
    ..The aim was to analyze the discordance rates in Hepatology between five h-I assessments from five databases: Scholar, Scopus, Web of Science (WoS), ScholarL restricted to "liver", and a specialty h-I HepaTop...
  46. pmc Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus
    V Thibault
    Laboratoire de Virologie, Service d Hepato gastro enterologie, Service des Maladies Infectieuses, Groupe Hospitalier Pitie Salpetriere, 75013 Paris, France
    J Clin Microbiol 37:3013-6. 1999
    ..This study demonstrates the emergence of particular genetic profiles in HBV-HIV-coinfected patients experiencing a loss of control of HBV infection despite high doses of lamivudine...
  47. pmc Hirsch index and truth survival in clinical research
    Thierry Poynard
    University Pierre et Marie Curie Assistance Publique Hôpitaux de Paris Liver Center, Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    PLoS ONE 5:e12044. 2010
    ..We hypothesized that publications with a first author having a higher Hirsch' index value (h-I), which quantifies and predicts an individual's scientific research output, should have a longer half-life...
  48. ncbi request reprint Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
    T Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Aliment Pharmacol Ther 15:355-61. 2001
    ..The total number of patients included was 1888, of which 945 received an active drug and 943 a placebo...
  49. doi request reprint [Treatment of chronic hepatitis B in HIV co-infected patients]
    J Massard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex, France
    Gastroenterol Clin Biol 32:S20-4. 2008
    ..In patients who had developed HBV lamivudine (or emtricitabine) resistance addition of tenofovir to antiretroviral regimen including maintenance of lamivudine or emtricitabine is the preferred choice...
  50. ncbi request reprint [Role of interferons in the treatment of hepatitis B and hepatitis C virus infections]
    P Cacoub
    Service de Medecine Interne, hôpital La Pitié Salpêtrière, 83, Boulevard de l Hopital, 75651 Paris, France
    Rev Med Interne 23:459s-474s. 2002
    ....
  51. doi request reprint Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus
    T Poynard
    Pitie Salpetriere, Universite Paris, Paris, France
    J Viral Hepat 16:203-13. 2009
    ..62 to 0.25) (P < 0.0001). FibroTest-ActiTest provides a quantitative estimate of liver fibrosis and necroinflammatory activity in patients with chronic hepatitis B and may be an alternative to reduce the need for liver biopsy...
  52. ncbi request reprint Natural history of HCV infection
    T Poynard
    Department of Internal Medicine, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Baillieres Best Pract Res Clin Gastroenterol 14:211-28. 2000
    ..In contrast severe extrahepatic manifestations are rare, with 1% for systemic vasculitis...
  53. doi request reprint Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials
    T Poynard
    Service d Hepatologie, UPMC Liver Center, hôpital La Pitié Salpêtrière, AP HP, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Gastroenterol Clin Biol 33:916-22. 2009
    ..The present report is a review of the evidence-based data published so far...
  54. doi request reprint Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update
    T Poynard
    APHP Service d Hépato Gastroentérologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris 6, CNRS ESA 8149 Paris, France
    Gastroenterol Clin Biol 32:8-21. 2008
    ....
  55. ncbi request reprint [Treatment and prevention of hepatitis C]
    T Poynard
    Service d hépato gastro entérologie Groupe hospitalier Pitié La Salpêtrière, Paris
    Rev Prat 50:1100-7. 2000
    ..Treatment of HCV should be systematically discussed in patients coinfected with HIV and HCV...
  56. ncbi request reprint Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
    F Imbert-Bismut
    Department of Biochemistry, , Paris, France
    Lancet 357:1069-75. 2001
    ..60 to 1.00 (34% [115] of all patients). INTERPRETATION: A combination of basic serum markers could be used to substantially reduce the number of liver biopsies done in patients with chronic HCV infection...
  57. ncbi request reprint Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation
    T Poynard
    APHP Groupe Hospitalier Pitié Salpétrière, Paris, France
    Aliment Pharmacol Ther 25:733-9. 2007
    ..Biopsy length and fragmentation are known as risk factors of false positive or false negative of biopsy but their quantitative impact on area under the receiver operating characteristic curve variability has not been assessed...
  58. ncbi request reprint Truth survival in clinical research: an evidence-based requiem?
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Ann Intern Med 136:888-95. 2002
    ..Factors associated with the survival of truth of clinical conclusions in the medical literature are unknown. The authors hypothesized that conclusions derived from studies using better methodology should have a longer half-life...
  59. ncbi request reprint [Update on the treatment of hepatitis B virus infection in patients infected by the human immunodeficiency virus]
    Y Benhamou
    Service d Hepato gastro enterologie, Hopital Pitie Salpetriere, 47, Boulevard de l Hopital, 75013 Paris, France
    Med Mal Infect 34:27-9. 2004
  60. doi request reprint Natural variability of NS3 protease in patients infected with genotype 4 hepatitis C virus (HCV): implications for antiviral treatment using specifically targeted antiviral therapy for HCV
    S Akhavan
    Department of Virology, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, and Université Pierre et Marie Curie Equipe de Recherche 1 Paris 6 University, Paris, France
    J Infect Dis 200:524-7. 2009
    ..The efficacy of antiprotease in HCV-4-infected patients remains to be proven in large clinical trials...
  61. doi request reprint HCV F1/F2 patients: treat now or continue to wait
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, Richmond, VA, USA Sercive d Hépatologie, Hopital Pitie Salpetriere, Paris, France
    Liver Int 34:79-84. 2014
    ..The factors which should be considered when deciding whether to treat a patient with HCV now or to delay treatment until IFN free therapies are available is discussed. ..
  62. ncbi request reprint Genetic heterogeneity of the hypervariable region I of Hepatitis C virus and lymphoproliferative disorders
    A Rigolet
    Virology Laboratory, Hopital Pitie Salpetriere, 75651 Paris, France
    Leukemia 19:1070-6. 2005
    ..Contrary to recent findings, our analysis based on multiple clones per patient analysis did not reveal any particular motif associated with BCLD...
  63. doi request reprint Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008
    L Michel
    INSERM U669, Paris, France
    J Viral Hepat 17:650-60. 2010
    ....
  64. ncbi request reprint Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    AIDS 21:1073-89. 2007
  65. ncbi request reprint Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus
    Yves Benhamou
    N Engl J Med 348:177-8. 2003
  66. ncbi request reprint Antiretroviral drugs and liver injury
    Vincent Soriano
    AIDS 22:1-13. 2008
  67. ncbi request reprint Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study
    Luz Martin-Carbonero
    Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 38:128-33. 2004
    ..The rate of complications due to end-stage liver disease will inevitably increase in this population, for whom anti-HCV therapy should be considered a priority...
  68. doi request reprint Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C
    Stefan Zeuzem
    JW Goethe University Hospital, Frankfurt, Germany
    Hepatology 48:407-17. 2008
    ..At week 12, mean treatment-associated missed workdays were significantly lower with alb-IFN 900 mug q2wk versus PEG-IFNalpha-2a (1.1 versus 4.3 days; P = 0.006)...
  69. ncbi request reprint Diagnostic value of FibroTest with normal serum aminotransferases
    Thierry Poynard
    Hepatology 43:374-5; author reply 375-6. 2006
  70. ncbi request reprint Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients
    Stephanie Dominguez
    Department of Infectious and Tropical Diseases INSERM U 720, CHU Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    AIDS 20:1157-61. 2006
    ..Treatment of acute hepatitis C (HCV) in HIV-infected patients has been poorly addressed...
  71. ncbi request reprint Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061
    Eva Herrmann
    Medizinische Klinik und Poliklinik, Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Antivir Ther 11:371-6. 2006
    ..Estimates of viral clearance and infected-cell loss support conclusions on these rates and on treatment mechanisms from previous studies on interferon-alpha-based treatments...
  72. ncbi request reprint Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    AIDS 19:221-40. 2005
  73. ncbi request reprint Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C
    Paula Braitstein
    British Columbia Center for Excellence in HIV AIDS, University of British Columbia, Vancouver, Canada
    AIDS 18:2221-34. 2004
    ..Evidence is accumulating regarding the impact of HIV/HCV coinfection on the response to, and safety and tolerability of, antiretroviral therapy (ART) in this population...
  74. ncbi request reprint [Management of HCV-HIV patients]
    Stanislas Pol
    Unité d Hépatologie, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris
    Gastroenterol Clin Biol 31:4S7-12. 2007
    ..The harmful impact of HIV underlines the need for improving:..
  75. ncbi request reprint Therapeutic management of hepatitis and HIV infection in co-infected patients: results of a survey performed before the 2005 Consensus Conference
    Dominique Salmon
    Infectious Diseases Unit, Cochin Hospital, Rene Descartes University, Paris V, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    J Hepatol 44:S2-5. 2006
    ..Recently published trials in co-infected patients and the outcome from this Consensus Conference will hopefully lead to wider access to anti-HCV therapy and better management of co-infected patients across Europe...
  76. doi request reprint Chronic hepatitis B: preventing, detecting, and managing viral resistance
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Clin Gastroenterol Hepatol 6:268-74. 2008
    ..Despite the substantial advances in treatment made to date, new agents with novel viral targets will be needed for patients who ultimately may fail second- or third-line therapy...
  77. doi request reprint Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 22:1399-410. 2008
    ..The present study represents an update of the current knowledge about HBV/HIV coinfection and an intent to provide practical advise about how to give the best care to HIV-infected persons with chronic hepatitis B...
  78. ncbi request reprint Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
    Holger Hinrichsen
    Medizinische Universitatsklinik, Kiel, Germany
    Gastroenterology 127:1347-55. 2004
    ..BILN 2061 is a potent and specific inhibitor of HCV serine protease in vitro. Preclinical toxicology data and studies in healthy volunteers supported the administration of BILN 2061 to patients with HCV infection...
  79. ncbi request reprint Erratum to 'The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting' [J. Clin. Virol. 41 (4) 2008 243-254]
    Stephen Barclay
    Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, United Kingdom
    J Clin Virol 42:104-15. 2008
    ..In all these conditions, awareness of possible HBV resistance to therapy must be kept in mind and HBV DNA levels monitored...
  80. ncbi request reprint Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
    Thierry Poynard
    Gastroenterology 128:1146-8; author reply 1148. 2005
  81. ncbi request reprint Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C
    Markus Reiser
    Ruhr Universitat Bochum, Bochum, Germany
    Hepatology 41:832-5. 2005
    ..A lower affinity of BILN-2061 for the NS3 protease of genotypes 2 and 3 HCV is most likely a major contributor to these findings...
  82. ncbi request reprint NNRTI-related or -unrelated hepatotoxicity?
    Pascal Lebray
    Hepatology 36:512-3; author reply 513-4. 2002
  83. ncbi request reprint Hepatitis B virus genotypes and extrahepatic manifestations
    Patrice Cacoub
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    J Hepatol 43:764-70. 2005
    ..This study aimed at correlating the presence of extrahepatic manifestations with hepatitis B virus (HBV) genotypes in patients with chronic HBV infection...
  84. ncbi request reprint Anemia and clinical outcomes in hepatitis C
    Yves Benhamou
    J Hepatol 47:7-9. 2007
  85. doi request reprint Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations
    Mona Munteanu
    Clin Biochem 41:1113-4. 2008
  86. ncbi request reprint Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection
    Laurent Vallat
    Department of Hematology, Assistance Publique Hopitaux, hôpital La Pitié Salpêtrière, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Arthritis Rheum 50:3668-78. 2004
    ..The objective of this study was to determine the frequency of circulating and liver-infiltrating monoclonal B cells in patients with HCV infection...
  87. doi request reprint The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting
    Stephen Barclay
    Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, United Kingdom
    J Clin Virol 41:243-54. 2008